• Molecular NameAlvimopan
  • SynonymADL 8-2698; alvimopan
  • Weight424.541
  • Drugbank_IDDB06274
  • ACS_NO156053-89-3
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.53
  • pkaN/A
  • LogD (pH=7, predicted)-0.98
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.97
  • LogSw (predicted, AB/LogsW2.0)0.37
  • Sw (mg/ml) (predicted, ACD/Labs)0.4
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds8
  • TPSA89.87
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug which behaves as a peripherally acting μ-opioid antagonist.
  • Absorption_valueN/A
  • Absorption (description)Alvimopan's high affinity for the peripheral mu-receptor results in an absolute oral bioavailability of less than 7%.
  • Caco_2N/A
  • Bioavailability6.0
  • Protein binding85.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAlvimopan undergoes no significant hepatic metabolism, but is metabolized by intestinal flora. Gut metabolism produces an active metabolite with no clinically significant contribution to drug effect.
  • Half life2.4~5.5h
  • ExcretionAlvimopan undergoes 35% renal excretion and greater than 50% biliary excretion.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A